Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer

NCT ID: NCT00165854

Last Updated: 2014-06-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 46 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-03-31

Brief Summary

Part 1: The primary purpose is to determine the recommended dose of E7070 in combination with capecitabine by dose adjustment. Part 2: The primary purpose is to determine the safety and efficacy of the combination in patients with metastatic CRC resistant to 5-fluorouracil and irinotecan.

Conditions

Colorectal Cancer (CRC)

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

E7070

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed solid tumour refractory to standard therapy or for whom no established therapy exists
• Age >= 18 years
• Karnofsky performance status of >= 70%
• Life expectancy of >= 3 months
• Absolute neutrophil count of >= 1.5 × 109/l, platelet count of ³ 100 × 109/l, haemoglobin level of ³ 10 g/dl (>= 6.2 mmol/l) (prior transfusion is permitted)
• Normal hepatic and renal function as defined by serum bilirubin £ 1.5 times the upper limit of normal, ALT and AST £ 2.5 times the upper limit of normal (£ 5 times the upper limit of normal in the presence of hepatic metastases), creatinine clearance ³ 50 ml/min (by Cockroft-Gault formula)
• Male and female patients
• Written informed consent to participate in the study

• Ambulant patients with progressive metastatic CRC who have received prior treatment with 5 FU and irinotecan and/or oxaliplatin either as single agents or in combination. Either 5 FU and/or irinotecan and/or oxaliplatin may have been administered in the adjuvant setting or for the treatment of metastatic disease. Patients who have received both 5-FU and irinotecan or oxaliplatin in the adjuvant setting only must have experienced disease recurrence within one year of starting chemotherapy.
• At least one unidimensionally measurable lesion according to the RECIST criteria
• Age ³ 18 years
• Karnofsky performance status of ³ 70%
• Life expectancy of ³ 3 months
• Absolute neutrophil count of ³ 1.5 × 109/l, platelet count of ³ 100 × 109/l, haemoglobin level of ³ 10 g/dl (³ 6.2 mmol/l) (prior transfusion is permitted)
• Normal hepatic and renal function as defined by serum bilirubin £ 1.5 times the upper limit of normal, ALT and AST £ 2.5 times the upper limit of normal (£ 5 times the upper limit of normal in the presence of hepatic metastases), creatinine clearance ³ 50 ml/min (by Cockroft-Gault formula)
• Male and female patients
• Written informed consent to participate in the study

Exclusion Criteria

• More than two previous courses of documented myelosuppresive chemotherapy (epidermal growth factor targeted therapy does not constitute a course of chemotherapy)
• CNS metastases (a CT or MRI scan should be done if there is a clinical suspicion of CNS metastases)
• Major surgery, chemotherapy or radiation therapy (except palliative) within 4 weeks of treatment start
• Previous investigational cytotoxic treatment for malignant disease within 30 days before the start of the study
• Any treatment with non-oncological investigational drugs within 30 days before the start of the study
• Pregnancy or breast feeding (all women of childbearing potential must have a pregnancy test before inclusion in the study; post-menopausal women must be amenorrhoeic for at least 12 months). Female patients must use adequate contraceptive protection.
• Fertile males not willing to use contraception or whose female partners are not using adequate contraceptive protection
• Uncontrolled infections
• Clinically significant cardiac impairment or unstable ischaemic heart disease including a myocardial infarction within three months of study entry
• History of alcoholism, drug addiction, or any psychiatric or psychological condition which in the opinion of the investigator would impair study compliance
• History of hypersensitivity to sulphonamides
• Prior severe or unexpected reaction to fluoropyrimidine therapy (which may be explained by dihydropyrimidine dehydrogenase deficiency or hypersensitivity to 5-FU)
• Malabsorption syndrome or other condition which may affect absorption of drug
• Concurrent or previous malignancy of a different tumour type within five years of starting the study except for adequately treated non-melanoma skin cancer or cervical intraepithelial neoplasia
• Treatment within two weeks before the start of the study with any of the following: coumarin anti-coagulants, terfenadine, cisapride, cyclosporin, tacrolimus, theophylline, diazepam, sulphonylurea hypoglycaemics, phenytoin, or carbamazepine
• Legal incapacity

• Prior chemotherapy other than 5-FU, irinotecan and/or oxaliplatin
• CNS metastases (a CT or MRI scan should be done if there is a clinical suspicion of CNS metastases)
• Major surgery, chemotherapy or radiation therapy (except palliative) within 4 weeks of treatment start
• Previous investigational cytotoxic treatment for malignant disease within 30 days before the start of the study
• Any treatment with non-oncological investigational drugs within 30 days before the start of the study
• Pregnancy or breast feeding (all women of childbearing potential must have a negative pregnancy test before inclusion in the study; post-menopausal women must be amenorrhoeic for at least 12 months). Female patients must use adequate contraceptive protection.
• Fertile males not willing to use contraception or whose female partners are not using adequate contraceptive protection
• Uncontrolled infections
• Clinically significant cardiac impairment or unstable ischaemic heart disease including a myocardial infarction within three months of study start
• History of alcoholism, drug addiction, or any psychiatric or psychological condition which in the opinion of the investigator would impair study compliance
• History of hypersensitivity to sulphonamides
• Prior severe or unexpected reaction to fluoropyrimidine therapy (which may be explained by dihydropyrimidine dehydrogenase deficiency or hypersensitivity to 5-FU)
• Malabsorption syndrome or other condition which may affect absorption of drug
• Concurrent or previous malignancy of a different tumour type within five years of starting the study except for adequately treated non-melanoma skin cancer or cervical intraepithelial neoplasia
• Treatment within two weeks before the start of the study with any of the following: coumarin anti-coagulants, terfenadine, cisapride, cyclosporin, tacrolimus, theophylline, diazepam, sulphonylurea hypoglycaemics, phenytoin, or carbamazepine
• Legal incapacity

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eisai Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jantien Wanders

Role: STUDY_DIRECTOR

Eisai Limited

Locations

Centre Léon Bérard

Lyon, , France

Institut Curie

Paris, , France

Universitätsklinikum der GHS-Essen

Essen, , Germany

Netherlands Cancer Institute

Amsterdam, , Netherlands

Countries

France; Germany; Netherlands

Other Identifiers

2004-002597-33

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

E7070-E044-209

Identifier Type: -

Identifier Source: org_study_id